← Latest news 
Cohance Lifesciences shares plunge 7 as Jefferies downgrades over weak Q4 visibility
Business
Published on 13 May 2026
Profit sinks 84% year on year as analysts disagree
Cohance Lifesciences shares fell around 7% after the company reported an 84% year-on-year drop in March-quarter net profit. Jefferies cut its target and downgraded the stock to Underperform, pointing to management instability and weak visibility into performance. Goldman Sachs kept a Buy rating, citing longer-term opportunities despite a rough near-term outlook.
- Shares slipped about 7% following an 84% year-on-year profit drop
- Jefferies downgraded to Underperform citing weak management visibility
- Jefferies also cut its target price amid the weak quarter
- Goldman Sachs retained Buy, betting on longer-term upside
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times